Oliver Freudenreich, MD
Psychosis Clinical and Research Program, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts
- 27Articles
- 126.4KReads
- 2000–2025Active
- 73Collaborators
- 343Citations
About
Oliver Freudenreich, MD, is affiliated with the Psychosis Clinical and Research Program at Massachusetts General Hospital/Harvard Medical School. With publications spanning from 2000 to 2025, Freudenreich has contributed extensively to research on schizophrenia, schizoaffective disorders, metabolic complications related to psychiatric treatment, neurology, addiction, bipolar and mood disorders, and patient care during the COVID-19 pandemic. His work includes studies on antipsychotic treatment strategies, adherence monitoring, and the clinical management of treatment-resistant cases. Frequent collaborators include Donald C. Goff, A. Eden Evins, and David C. Henderson.
Publications
Brexpiprazole for the Treatment of Co-Occurring Schizophrenia and Substance Use Disorder
October 13, 2025
Comprehensive Evaluation Detects Seizure Disorder That Exacerbated Catatonia and Treatment-Resistant Schizophrenia
December 22, 2022
Long-Acting Injectable Antipsychotic Management During COVID-19
January 12, 2021
Lamotrigine Cross-Reactivity With Phencyclidine in a Research Study
July 26, 2018
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.